'Ketamine' nasal spray approved for treating depression in US
Esketamine is administered as a nasal spray and was approved by the Food and Drug Administration (FDA) this week after trials showing it could relieve depressive symptoms within hours.
“[That speed] is a huge thing because depressed patients are very disabled and suffer enormously,” said Dr John Mann, a psychiatrist and researcher at Columbia University.
Esketamine is the first approved depression treatment for more than 30 years to act on the brain in a unique way, and will be offered to patients who have tried at least two other treatments without success.
Because of the potential for abuse, esketamine is administered under medical supervision, with patients supervised for two hours afterwards.